…treatment with Denosumab or Zometa is as supportive care, not as cancer treatment like EXEL184 is testing.
This distinction is more semantic than scientific. All drugs used in the kinds of metastatic cancers we’re discussing are “supportive” insofar as the disease itself is terminal.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”